Takeda Receives Positive CHMP Opinion Recommending Approval of Dengue Vaccine Candidate in EU and Dengue-Endemic Countries
Positive Opinion for TAK-003 Based on 4.5 Years of Safety and Efficacy Data from Pivotal Phase 3 Trial of 20,000 Children and Adolescents Across Eight Dengue-Endemic Countries. Marketing Authorization Expected in Coming Months in Europe Followed by Regulatory Approvals in Latin America and Asia.